soul trial oral semaglutide cardiovascular outcomes 2024 results mace 🧿 is the first oral GLP-1 Cardiovascular Outcomes, Safety, and Tolerability

The main characteristics of the studies selected for the pooled analysis are presented in Table 1

In September 2023, the Phase 2b trial results of pegozafermin were published in NEJM

Zepbound (approved in late 2023) is rapidly capturing share from semaglutide due to superior efficacy Ozmosi

Jonathan also gave us a few examples of compounding pharmacies that produce GLP-1s: Olympia Pharmaceuticals Atlas Pharmaceuticals, LLC Apothecary Pharma, LLC Arc Compounding Pharmacy LLC Assure Infusions, Inc

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials

Before we can talk about shelf life, we have to be on the same page about the process itself